Posted Aug. 24, 2010 at 6:47 a.m.
LabCorp
LabCorp launches genetic test for hepatitis C therapy reaction
Post a comment
Print this blog postE-mail blog post
Share
LabCorp
On The Web
Site Search
Local Tech Wire
BURLINGTON, N.C. – Laboratory Corporation of America (NYSE: LH) is rolling out a new genetic test designed to determined a person’s reaction to some hepatitis C virus therapies.
Some patients respond with limited efficacy to certain interferon-based therapies. The test is intended to determine patients who are likely to have what LabCorp describes as a “favorable response.”
More than 3 million people in the U.S. and 170 million people worldwide are infected with hepatitis C.
For details, read here.
Get the latest news alerts: Follow LTW at Twitter.
Featured
E-mail Preferences
The Skinny
- Will RTP-based ChannelAdvisor go public? They're thinking
- What brands are winning Super Bowl hype? Two Durham firms to find out
- In Super Bowl of social media, Patriots win, Triangle firm says
- Big job cuts coming at IBM? Don't be surprised
- Erskine Bowles is among those who can cash in big time on Facebook IPO
- Ignore Facebook hype - Check out 'risk factors,' too
- Facebook vs. Google IPO: Which deal ranks better?
- Triangle StartUp Factory says business already booming
- Entrepreneurship remains at heart of Tech Wire mission
- Flashback: Tech Wire launched 10 years ago today